FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168408099> ?p ?o ?g. }

• W2168408099 endingPage "713" @default.
• W2168408099 startingPage "709" @default.
• W2168408099 abstract "Actinic keratoses (AKs) are epidermal skin lesions with the potential to develop into invasive squamous cell carcinoma (SCC). Treatment at an early stage may prevent development of SCC. Current treatment options are highly destructive and associated with significant side-effects. Early studies with topical diclofenac were encouraging and led to its evaluation for the treatment of actinic keratosis. Previous studies have demonstrated that 3% diclofenac in 2.5% hyaluronan gel is effective and well tolerated in the treatment of AK. The present study was designed to further explore the therapeutic potential of this gel.This randomized, double-blind, placebo-controlled trial involved outpatients with a diagnosis of five or more AK lesions contained in one to three 5 cm(2) blocks. Patients received either active treatment (3% diclofenac gel in 2.5% hyaluronan gel) or inactive gel vehicle (hyaluronan) as placebo (0.5 g b.i.d. in each 5 cm(2) treatment area for 90 days). Assessments included the Target Lesion Number Score (TLNS), Cumulative Lesion Number Score (CLNS), and Global Improvement Indices rated separately by both the investigator (IGII) and patient (PGII).Results obtained from 96 patients at follow up (30 days after end of treatment) indicated that a significantly higher proportion of patients who received active treatment had a TLNS = 0 compared to the placebo group (50% vs. 20%; P < 0.001). There was also a significant difference between the two groups in CLNS, with 47% of patients in the active treatment group having a CLNS = 0 compared with only 19% in the placebo group (P < 0.001). The proportion of patients with an IGII score of 4 (completely improved) at follow-up was 47% in the active treatment group compared with only 19% in the placebo group (P < 0.001); for PGII these values were 41% vs. 17%, P < 0.001. Both treatments were well tolerated, with most adverse events related to the skin.Topical 3% diclofenac in 2.5% hyaluronan gel was effective and well tolerated for the treatment of AK." @default.
• W2168408099 created "2016-06-24" @default.
• W2168408099 creator A5008914021 @default.
• W2168408099 creator A5044008591 @default.
• W2168408099 creator A5066895762 @default.
• W2168408099 creator A5074073705 @default.
• W2168408099 date "2001-11-01" @default.
• W2168408099 modified "2023-10-14" @default.
• W2168408099 title "Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses" @default.
• W2168408099 cites W1965067812 @default.
• W2168408099 cites W1979559178 @default.
• W2168408099 cites W1985187105 @default.
• W2168408099 cites W1993762151 @default.
• W2168408099 cites W1993827451 @default.
• W2168408099 cites W1998419710 @default.
• W2168408099 cites W2003041198 @default.
• W2168408099 cites W2007233628 @default.
• W2168408099 cites W2022566446 @default.
• W2168408099 cites W2023595441 @default.
• W2168408099 cites W2049279480 @default.
• W2168408099 cites W2059916616 @default.
• W2168408099 cites W2064727610 @default.
• W2168408099 cites W2073581208 @default.
• W2168408099 cites W2094927565 @default.
• W2168408099 cites W2134911699 @default.
• W2168408099 cites W2327667256 @default.
• W2168408099 cites W2418387125 @default.
• W2168408099 cites W4232177050 @default.
• W2168408099 doi "https://doi.org/10.1046/j.1365-4362.2001.01324.x" @default.
• W2168408099 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11737438" @default.
• W2168408099 hasPublicationYear "2001" @default.
• W2168408099 type Work @default.
• W2168408099 sameAs 2168408099 @default.
• W2168408099 citedByCount "208" @default.
• W2168408099 countsByYear W21684080992012 @default.
• W2168408099 countsByYear W21684080992013 @default.
• W2168408099 countsByYear W21684080992014 @default.
• W2168408099 countsByYear W21684080992015 @default.
• W2168408099 countsByYear W21684080992016 @default.
• W2168408099 countsByYear W21684080992017 @default.
• W2168408099 countsByYear W21684080992018 @default.
• W2168408099 countsByYear W21684080992019 @default.
• W2168408099 countsByYear W21684080992020 @default.
• W2168408099 countsByYear W21684080992021 @default.
• W2168408099 countsByYear W21684080992022 @default.
• W2168408099 countsByYear W21684080992023 @default.
• W2168408099 crossrefType "journal-article" @default.
• W2168408099 hasAuthorship W2168408099A5008914021 @default.
• W2168408099 hasAuthorship W2168408099A5044008591 @default.
• W2168408099 hasAuthorship W2168408099A5066895762 @default.
• W2168408099 hasAuthorship W2168408099A5074073705 @default.
• W2168408099 hasBestOaLocation W21684080992 @default.
• W2168408099 hasConcept C126322002 @default.
• W2168408099 hasConcept C141071460 @default.
• W2168408099 hasConcept C142724271 @default.
• W2168408099 hasConcept C16005928 @default.
• W2168408099 hasConcept C168563851 @default.
• W2168408099 hasConcept C204787440 @default.
• W2168408099 hasConcept C27081682 @default.
• W2168408099 hasConcept C2777873816 @default.
• W2168408099 hasConcept C2779826273 @default.
• W2168408099 hasConcept C2781156865 @default.
• W2168408099 hasConcept C2910086692 @default.
• W2168408099 hasConcept C3019992690 @default.
• W2168408099 hasConcept C42219234 @default.
• W2168408099 hasConcept C71924100 @default.
• W2168408099 hasConceptScore W2168408099C126322002 @default.
• W2168408099 hasConceptScore W2168408099C141071460 @default.
• W2168408099 hasConceptScore W2168408099C142724271 @default.
• W2168408099 hasConceptScore W2168408099C16005928 @default.
• W2168408099 hasConceptScore W2168408099C168563851 @default.
• W2168408099 hasConceptScore W2168408099C204787440 @default.
• W2168408099 hasConceptScore W2168408099C27081682 @default.
• W2168408099 hasConceptScore W2168408099C2777873816 @default.
• W2168408099 hasConceptScore W2168408099C2779826273 @default.
• W2168408099 hasConceptScore W2168408099C2781156865 @default.
• W2168408099 hasConceptScore W2168408099C2910086692 @default.
• W2168408099 hasConceptScore W2168408099C3019992690 @default.
• W2168408099 hasConceptScore W2168408099C42219234 @default.
• W2168408099 hasConceptScore W2168408099C71924100 @default.
• W2168408099 hasIssue "11" @default.
• W2168408099 hasLocation W21684080991 @default.
• W2168408099 hasLocation W21684080992 @default.
• W2168408099 hasLocation W21684080993 @default.
• W2168408099 hasOpenAccess W2168408099 @default.
• W2168408099 hasPrimaryLocation W21684080991 @default.
• W2168408099 hasRelatedWork W1837735082 @default.
• W2168408099 hasRelatedWork W1973121679 @default.
• W2168408099 hasRelatedWork W1983893753 @default.
• W2168408099 hasRelatedWork W2017154835 @default.
• W2168408099 hasRelatedWork W2019138032 @default.
• W2168408099 hasRelatedWork W2024652914 @default.
• W2168408099 hasRelatedWork W2030847199 @default.
• W2168408099 hasRelatedWork W2105808906 @default.
• W2168408099 hasRelatedWork W2538229076 @default.
• W2168408099 hasRelatedWork W4242386261 @default.
• W2168408099 hasVolume "40" @default.
• W2168408099 isParatext "false" @default.

• next